drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy; CAR T)
drug_description
Autologous gene-modified T cells engineered to express a second-generation anti-GD2 chimeric antigen receptor (CD3ΞΆ plus co-stimulatory domain), coexpressing interleukin-15 to enhance persistence and expansion, and incorporating an inducible caspase-9 (iC9) safety switch for controlled elimination.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically engineered to express a second-generation anti-GD2 CAR (CD3zeta plus a co-stimulatory domain) that redirects T-cell recognition and cytotoxicity against GD2-positive tumor cells; coexpressed IL-15 enhances T-cell persistence and expansion in vivo; an inducible caspase-9 (iC9) safety switch enables pharmacologic elimination of the cells to control toxicity.
drug_name
iC9.GD2.CAR.IL-15 T cells
nct_id_drug_ref
NCT05620342